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___________________________________________________________________________________________ 
 
Abstract  
Fibrosis is characterized by extracellular matrix 
(ECM) remodeling and stiffening. However, the 
functional contribution of tissue stiffening to non-
cancer pathogenesis remains largely unknown. 
Fibronectin (Fn) is an ECM glycoprotein 
substantially expressed during tissue repair. Here we 
show in advanced chronic liver fibrogenesis using a 
mouse model lacking Fn that, unexpectedly, Fn-null 
livers lead to more extensive liver cirrhosis, which is 
accompanied by increased liver tissue stiffness and 
deteriorated hepatic functions. Furthermore, Fn-null 
livers exhibit more myofibroblast phenotypes, and 
accumulate highly disorganized/diffuse collagenous 
ECM networks composed of thinner and 
significantly increased number of collagen fibrils 
during advanced chronic liver damage. 
Mechanistically, mutant livers show elevated local 
TGF-β activity and lysyl oxidase expressions. A 
significant amount of active lysyl oxidase is released 
in Fn-null hepatic stellate cells in response to TGF-
β1 through canonical and non-canonical Smad such 
as PI3 kinase-mediated pathways. TGF-β1-induced 
collagen fibril stiffness in Fn-null hepatic stellate 
cells is significantly higher compared to wild-type 
cells. Inhibition of lysyl oxidase significantly 
reduces collagen fibril stiffness, and treatment of Fn 
recovers collagen fibril stiffness to wild-type levels. 
Thus, our findings indicate an indispensable role for 
Fn in chronic liver fibrosis/cirrshosis in negatively 
regulating TGF-β bioavailability, which in turn 
modulates ECM remodeling and stiffening, and 
consequently preserves adult organ functions. 
Furthermore, this regulatory mechanism by Fn could 
be translated for a potential therapeutic target in 
broader variety of chronic fibrotic diseases. 
 
__________________________________________ 
 
Introduction 
Fibrosis is a part of the wound-healing response that 
maintains organ structure and integrity following 
tissue damage. However excessive fibrosis 
contributes to a number of diseases such as liver 
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fibrosis (1). Liver fibrosis is defined as an abnormal 
response of the liver to persistent injury and affects 
tens of millions of people worldwide (2). It is caused 
by hepatotropic virus infection, drug and alcohol 
abuse. Liver fibrosis is of great clinical importance 
since normal liver architecture is disrupted and liver 
function is ultimately impaired. There is no effective 
treatment for liver fibrosis and many patients end up 
with a progressive form of the disease, liver cirrhosis, 
often requiring a liver transplant (3,4). The hallmark 
of liver fibrosis is excessive accumulation of mainly 
type I collagen-containing extracellular matrices 
(ECMs), and therefore involves both wound healing 
and fibrotic processes. ECM production and 
remodeling in the liver following injury involves the 
activation of specific cell types, hepatic stellate cells, 
which transdifferentiate into contractile and 
proliferative myofibroblasts (5-7). 
    Collagen is the most abundant scaffolding ECM 
in tissue/organ stroma and contributes significantly 
to tissue/organ integrity (8). The Lysyl oxidase 
(LOX) family enzymes are copper-dependent amine 
oxidases that catalyze the process of covalent 
crosslinking of collagen by oxidatively deaminating 
specific lysine and hydroxylysine residues in the 
telopeptide domains, which increases collagen 
stiffness (9,10). Collagen crosslinking stiffens the 
ECM and has been implicated in cancer cell invasion 
(11). Collagen crosslinking also accompanies tissue 
fibrosis mediated by several profibrogenic cytokines 
(12). However, the functional contribution of 
collagen crosslinking to non-cancer pathogenesis 
remains largely unknown.    
    Transforming growth factor (TGF)-β is a 
profibrogenic master cytokine responsible for 
promoting differentiation of  tissue-resident 
fibroblasts into myofibroblasts, upregulation of 
ECM production including fibronectin (Fn), and 
downregulation of ECM degradation (13). Growing 
evidence suggests a mechanism by which Fn plays a 
role in TGF-β signaling (14). Fn is involved in the 
initial incorporation of latent TGF-β-binding protein 
(LTBP)-1 into the ECM in vitro (15). TGF-β is 
secreted in a biologically inactive (latent) form in a 
complex (large latent complex [LLC]) with TGF-β 
latency associated protein (LAP) and LTBPs (16). 
The extracellular TGF-β activity in response to 
injury is regulated by the local activation of latent 
TGF-β complex to active TGF-β. Indeed, elevated 
TGF-β bioavailability is frequently observed in 
chronic fibrotic diseases, and the inhibition of local 
TGF-β activation can protect against the progression 
of fibrosis in several adult chronic fibrotic diseases 
(17-20). In spite of numerous in vitro studies and 
animal models, TGF-β/Fn interdependence in the 
fibrogenic response to advanced chronic liver 
damage has not yet been addressed in vivo.  
    Fn is a large dimeric glycoprotein that exists in 
blood plasma in its soluble form (plasma type) and 
in its insoluble form (cellular type) as a part of the 
ECM of almost every tissue in an organism. Plasma 
Fn is produced solely by hepatocytes in the liver 
(21,22). Extensive in vitro functional studies have 
indicated that Fn plays a key role in a wide range of 
cellular behaviors (21,22), and prominent expression 
of Fn is observed in response to liver injury (23). 
Based on in vitro findings, it has been postulated that 
collagen network formation depends on the Fn 
matrix (24,25). We therefore hypothesized that 
removal of Fn from the in vivo system could prevent 
extensive ECM network formation following tissue 
damage. To define the functional identity of Fn in 
adult tissue remodeling, we recently established a 
null-condition for both Fn isoforms in adult liver. 
We demonstrated a Fn-independent mechanism of 
collagen fibrillogenesis and identified TGF-β-
signaling and type V collagen as essential elements 
for collagen fibrillogenesis in response to liver 
injury (26). However, it remains unknown whether 
the extent of the initial Fn deposition could 
contribute to the critical turning point from normal 
to abnormal healing during the development of 
chronic tissue fibrosis. Furthermore, it is also 
unclear how ECM remodeling by myofibroblasts 
results in changes in mechanical tension and 
supports the activation of pathogenic signaling 
pathways. Here, we have addressed the molecular 
mechanism responsible for tissue stiffness in 
advanced chronic liver fibrogenesis using a mouse 
model lacking both Fn isoforms in the adult liver. 
 
 
 
Experimental Procedures  
 
Maintenance of mice 
Mice lacking both plasma and cellular type 
fibronectin in the liver (liver Fn-null mice) were 
generated by intraperitoneal injections of 
polyinosinic-polycytidic acid (pI-pC) in the 
Fn(fl/fl)/Mx-Cre+ strain as described previously 
(26). Fn-null livers showed normal liver morphology, 
and no obvious inflammation or fibrosis was noted 
after pI-pC injections (26). All mice were 
maintained and bred at the animal facility in the 
Cleveland Clinic, OH, USA, and the University of 
Liverpool, Liverpool, UK, in accordance with 
institutional guidelines. Mice were regularly 
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monitored and had free access to standard mouse 
chow and water. Mice received humane care in 
accordance with institutional guidelines. 
 
Induction of chronic liver injury by carbon 
tetrachloride (CCl4) 
Chronic liver injury was induced intraperitoneally by 
administrations of CCl4 solution in olive oil (Fluka) 
(0.5 ml/kg body weight as 50% [vol/vol], twice a 
week for up to 17 weeks) in sex-matched, 12- to 15-
week-old mice (26,27). Control and liver Fn-null 
mice were derived from the same litters. Mice 
injected only with olive oil as negative controls 
showed no phenotypes (data not shown). 
 
Antibodies, cytokines and reagents 
The following antibodies were used for the analyses: 
rabbit polyclonal antibody (pAb) against mouse 
fibronectin (Chemicon); rabbit mAb (E184, 
Epitomics) against αSMA; rabbit pAb against 
pSmad3 which specifically recognizes the 
phosphorylated C-terminal serine 423/425 of Smad3 
(also cross-reacted with phosphorylated C-terminal 
serine 465/467 of Smad2) (a kind gift from Dr. 
Koichi Matsuzaki, Kansai Medical University, 
Osaka, Japan); rabbit pAb against LOX (Sigma-
Aldrich); rabbit pAb against cleaved caspase3 (Cell 
Signaling); mouse mAb against HSC70 (Santa 
Cruz); mouse mAb against β-actin (clone AC15, 
Sigma); affinity-purified rabbit pAbs against mouse 
LAP of TGF-β1, mouse LTBP-3, human LTBP-4, 
and human type V collagen (26). The preparation 
and characterization of rabbit pAbs against bovine 
type I collagen and type III procollagen have been 
described elsewhere (28). Rabbit pAb against human 
lysyl oxidase was generated using its protein residue 
#22-168 expressed in HEK293 cells as an antigen 
and affinity purified as described (29). Rabbit pAb 
against LTBP-1 was a kind gift from Dr. Lynn Sakai 
(Research Center, Shriners Hospitals for Children, 
Portland, OR, USA). FITC- and Cy3-conjugated 
donkey anti-rabbit IgG, and peroxidase-conjugated 
donkey anti-mouse and anti-rabbit IgG were from 
Jackson ImmunoRes Lab. 4’6-diamidino-2-
phenylindole (DAPI) was from Molecular Probes. 
EnvisionTM+ System-HRP labeled polymer was from 
DAKO. Recombinant human TGF-β1 was from 
R&D Systems. Bovine plasma fibronectin was from 
Sigma. All inhibitors were from Calbiochem.  
 
Histological analysis, immunohistochemistry and 
immunofluorescence, and transmission electron 
microscopy  
For histological analysis, liver samples were either 
directly frozen in OCT compound (Tissue-Tek, 
Sakura Finetek) or fixed overnight in 4% 
paraformaldehyde in PBS, pH 7.2, and dehydrated in 
a graded alcohol series before being embedded in 
paraffin. Sirius Red staining was performed 
according to standard protocols. 
Immunohistochemistry and immunofluorescence 
studies were performed as described previously 
(30,31). Double-immunohistochemical analysis with 
paraffin-embedded tissue sections was performed as 
described (26). Briefly, after the first antigen-
antibody reaction, the slides were incubated with 
dissociation buffer containing 0.1 M Glycine-HCl 
(pH 2.2) to dissociate immunoglobulins from 
antigenic sites. Then the second antigen-antibody 
reaction was subsequently performed. We carried 
out the second reaction without antibodies and 
confirmed the complete dissociation of the first 
immunoglobulins. 
For quantification of fibrotic areas in response to 
chronic liver injury and LOX signal intensity in 
hepatic stellate cells, images were captured with the 
same gain, offset, magnitude and exposure time. A 
minimum of 5 different images were randomly 
selected, and intensities were quantified using 
ImageJ software (version 1.48, US National 
Institutes of Health). For cellular signal intensity, the 
mean intensity in each cell (intensities/areas, 50 
cells) was measured and the average intensity per 
cell (relative fluorescent units) was calculated as 
described elsewhere (32).   
    Transmission electron microscopy (TEM) was 
performed as described previously (26).  
 
Polarization microscopy analysis 
Quantitative polarization microscopic analysis was 
performed on Sirius red stained sections using 
Abrio™ LS PolScope (CRI Inc., Woburn, MA) (33). 
In PolScope images, the brightness of each pixel is 
strictly proportional to birefringence “retardance” of 
the particular object point and independent of its 
slow axis orientation (34). Measured retardances and 
orientations are represented as pseudo-colors. 
Images make it possible to determine specimen 
anisotropy (retardance and azimuth) at all angles 
(360°) simultaneously, and permit quantitative 
measurements on the orientation and the degree of 
organization of the fibers (35). In the present 
analysis, any azimuth (slow axis orientation) was 
covered by a 180° range because a fiber bundle has 
no head or tail. Fiber retardations and orientations 
were assessed with an automated analyzing system. 
Fifty measurements were taken in each of the three 
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regions and averaged. The degree of fiber alignment 
is represented by a calculation of the angular 
deviation of each orientation distribution. Thus, the 
smaller the angular deviation, the more aligned the 
fibers are.  
 
Atomic force microscopy (AFM) analysis 
The nanomechanical properties of the liver sections 
were investigated with atomic force microscopy 
(AFM: NanoScope VIII MultiMode AFM, Bruker 
Nano Inc., Santa Barbara, CA). The AFM was 
equipped with a 150 × 150 × 5 µm scanner (J-
scanner) operated with the Peakforce Quantitative 
Nanomechanical Mapping (PFQNM) modality. 
Liver samples were rapidly frozen in OCT 
compound (Tissue-Tek, Sakura Finetek) following 
which 10 µm thick sections were prepared using a 
cryostat (Leica CM1950, Leica Microsystems, UK) 
and adhered to glass slides coated with Vectabond 
(Vector Laboratories Ltd). Cells were directly 
seeded on glass coverslips and cultured for 7 days. 
Then the glass slides/cover slips were adhered to 
metal support stubs using adhesive pads, and the 
samples were imaged at ambient conditions using a 
silicon nitride tip. The tip had a nominal tip radius of 
8 nm and a 5 N/m spring constant (Bruker TAP150A 
probe). The preparation method used for the AFM 
imaging maintained the tissue/cellular structure for 
imaging without the need for any chemical fixation. 
The PFQNM method was calibrated using a 
reference polymer (PS1, Vishay Measurements 
Group UK) with a known elastic modulus (2.8 ± 0.1 
GPa). The spring constant and deflection sensitivity 
was calibrated using the reference sample and the 
same AFM probe was used for imaging every 
sample. The data were fitted with the Derjaguin–
Muller–Toporov (DMT) model to extract the elastic 
modulus, as described previously (36).  For tissue 
samples, 10 x 10 µm images were collected and the 
mean elastic modulus was determined using Bruker 
Nanoscope software, v 1.5. Each image had a 
resolution of 384 samples/line. The regions selected 
for AFM were guided by Sirius Red-stained images 
of serial sections. Smaller scans (2 x 2 µm) were 
conducted in collagen fibril-rich areas and used to 
determine the elastic modulus distribution pixel-by-
pixel in these locations. A Gaussian fit was applied 
to the data. For cell culture samples, collagen fibril 
areas were selected from 5 x 5 µm scan images, and 
the mean elastic modulus for collagen fibrils were 
determined from 0.5 x 0.5 µm scans. 
 
Real-time PCR  
Real-time PCR was performed as described 
previously (37). The following primers were used:  
ColIa1 forward, 5’-
GGGCGAGTGCTGTGCTTT-3’;  
ColIa1 reverse, 5’-
GGTCCCTCGACTCCTACATCTTC-3’;  
Col3a1 forward, 5’-
CTGTAACATGGAAACTGGGGAAA-3’;  
Col3a1 reverse, 5’-
CCATAGCTGAACTGAAAACCACC-3’;  
Col5a1 forward, 5'-
GAGGACCACACAGGGAAGC-3';  
Col5a1 reverse, 5'-
CTTGTAGACACTGAGAGCAATTCG-3';  
MMP8 forward, 5’-
GGGATTATGGAAATGCCTCGAT-3’; 
MMP8 reverse, 5’-
CTGTTTTCACTTCAGCCCTTGA-3’; 
MMP13 forward, 5’-
CTTCTTCTTGTTGAGCTGGACTC-3’; 
MMP13 reverse, 5’-
CTGTGGAGGTCACTGTAGACT-3’;    
LOX forward, 5’-
CCTATGCGGCAGACATAGACT-3’; 
LOX reverse, 5’-
CCAGGTAGCTGGGGTTTACA-3’; 
LOXL1 forward, 5’-
ATGTGCAGCCTGGGAACTAC-3’; 
LOXL1 reverse, 5’-
CACCACGTTGTTGGTGAAGT-3’; 
LOXL2 forward, 5’-
CGTTGGAGTGGTGTGTAGTGAG-3’; 
LOXL2 reverse, 5’-
CGAAAGGCAGAAAGGATGG-3’; 
LOXL3 forward, 5’-
GCCACGTAGTCTGCGGTATG-3’; 
LOXL3 reverse, 5’-
AGGGAGAGGTGGGCTTCTGT-3’; 
LOXL4 forward, 5’-
GCCGCTGCAAGTATGATGG-3’; 
LOXL4 reverse, 5’-
CCTGAGTCGCTGTTCCTGCT-3’; 
18S rRNA forward, 5’-
GGCGACGACCCATTCG-3’;  
18S rRNA reverse, 5’-
ACCCGTGGTCACCATGGTA-3’.  
All samples were analyzed in triplicate as a 
minimum. After the reactions, the specificity of 
amplifications in each sample was confirmed by 
dissociation analysis, showing that each sample gave 
a single melting peak. The relative mRNA levels 
were normalized to the level of 18S rRNA.  
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Western-blot analysis  
Western blot analyses were performed as described 
elsewhere (31). In some immunoblotting analyses, 
samples were transferred onto an Immobilon-FL 
polyvinylidene fluoride (PVDF) membrane 
(Millipore Corp.) and probed with primary and 
IRDye 800CW- or IRDye 680-conjugated secondary 
antibodies (LI-COR Biosci.). Immunoreactive bands 
were detected using the Odyssey Infrared Imaging 
System (LI-COR Biosci.).  
 
TGF-β bioassay 
A mink lung cell line (TMLC) stably transfected 
with a plasminogen activator inhibitor-1 (PAI-1) 
promoter fused to luciferase was used for the 
analysis (38). Active TGF-β levels were measured as 
described elsewhere (32).  
 
Hydroxyproline assay 
Hydroxyproline content was measured as described 
elsewhere (26).  
 
Hepatic biochemical markers  
Serum alanine aminotransferase (ALT) level was 
determined using a standard kit (Genzyme 
Diagnostics P.E.I. Inc., Canada). Serum total protein 
(by the Biuret method), albumin (by the BCG 
method), total bilirubin (by the Azobilirubin 
method), and cholinesterase (by the p-
Hydroxybenzolcholine method) levels were 
measured using the Hitachi 7180 Auto Analyzer 
(Japan).  
 
In vitro assay using mouse hepatic stellate cell 
lines 
Control and Fn-null mouse hepatic stellate cell lines 
were established from adult primary hepatic stellate 
cell cultures under p21-null genetic background as 
described previously (26) and used for the analysis 
presented in this study. Briefly, hepatic stellate cells 
were isolated from adult Fn(flox/flox)/p21(-/-) 
mouse liver as parental cells, and subsequently those 
lines were treated with Cre-transducing adenovirus 
to delete Fn-floxed genes (Fn-null hepatic stellate 
cells). Established cell lines showed similar 
morphology and typical activated hepatic stellate 
cell phenotypes (26). To examine the effects of 
TGF-β1 on LOX production, hepatic stellate cells 
were cultured for 8 h with Dulbecco’s modified 
Eagle’s medium (DMEM) containing 8 % Fn-
depleted FBS. The medium was then replaced with 
DMEM without FBS containing 0.2 mM ascorbic 
acid and 2 pM TGF-β1. Cells were then incubated 
for 18 h and used for the analysis. To examine the 
inhibitory effect of collagen crosslinking, cells were 
treated with β-aminopropionitrile (BAPN, 200 µM: 
Fisher Scientific) containing DMEM, 8 % Fn-
depleted FBS, 0.2 mM ascorbic acid and 2 pM TGF-
β1, then incubated for 7 days and used for the 
analysis. We confirmed that the concentration of 
BAPN used did not affect stellate cell proliferation 
(data not shown). To examine the effect of Fn on 
formed collagen stiffness, cells were cultured for 7 
days with DMEM containing 8 % Fn-depleted FBS, 
0.2 mM ascorbic acid and 10 µg/ml plasma Fn, then 
used for the analysis. To examine the signaling axis 
in TGF-β1-mediated LOX production, Fn-null 
stellate cells were cultured for 24 h with DMEM 
containing 8 % Fn-depleted FBS. The medium was 
then replaced with DMEM containing 0.2 mM 
ascorbic acid without FBS and with indicated 
supplements. Cells were preincubated for 1 hr, then 
treated with 2 pM TGF-β1, further incubated for 18 
h, then analyzed. Where indicated, cultures 
contained 10 µM SIS3 (IC50=3 µM) to inhibit 
Smad3, 10 µM LY294002 (IC50=1.4 µM) to inhibit 
phosphatidylinositol 3 (PI3)-kinase, 10 µM 
PD169316 (IC50=89 nM) to inhibit p38 MAP kinase, 
5 µM 420119 (IC50=40 nM) to inhibit c-Jun N-
terminal kinase (JNK), and 20 µM PD98059 (IC50=2 
µM) to inhibit mitogen-activated protein kinase 
kinase (MEK)1/2. We confirmed that the 
concentration of the inhibitors used did not affect 
stellate cell proliferation (data not shown).   
 
 
Data presentation and statistical analysis 
All experiments were performed in triplicate as a 
minimum, on separate occasions, and the data shown 
were chosen as representative of results consistently 
observed. Results are presented as means ± standard 
deviation (S.D.). Differences between selected 
groups were analyzed using the Mann-Whitney U 
test. In cases where more than two groups were 
compared, the Steel-Dwass test was used. A P value 
of <0.05 was considered significant. 
 
 
 
Results  
 
More extensive fibrosis/cirrhosis in mice lacking 
Fn during CCl4-induced advanced stages of 
chronic liver injury.   
Based on our previous finding that Fn-deficiency did 
not interfere with reconstruction and resolution of 
collagen organization in initial stages of liver 
damage (26), we hypothesized that Fn-deficiency 
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 6 
may not affect the reconstruction of ECM 
architectures even in advanced stages of chronic 
liver damage. To address functional roles of Fn 
during this process, chronic liver fibrosis was 
induced in a well-established mouse model where 
injury is brought on by treatment with a liver-
damaging agent, carbon tetrachloride (CCl4, 0.5 
ml/kg weight, twice a week for 17 weeks) (27). 
While increased expression of Fn protein was 
observed in control livers after injury, its expression 
in mutant livers (Fn(fl/fl)/Mx-Cre+) was remarkably 
low throughout the experimental period (time 0 
through 17 weeks during CCl4 injections). The Fn 
level in mutant livers at 17 weeks of CCl4 treatment 
was only ~2% of that in control livers (P < 0.01) as 
shown by Western analysis (Fig. 1A; and data not 
shown). These data confirmed that neither Fn 
isoform was induced in mutant livers during 
advanced chronic injury. Anatomical and 
histological analyses revealed no abnormalities in 
Fn-null livers under standard laboratory conditions 
((26), data not shown). 
    To determine whether Fn-deficiency affects CCl4-
induced liver damage during chronic injury, body 
weight changes, serum alanine aminotransferase 
(ALT, as a measure for hepatocyte damage) and 
albumin/globulin ratio (as a measure of net hepatic 
damage) were examined. These parameters showed 
similar patterns in both control and Fn-null livers 
during 17 weeks of CCl4 treatment. Both showed no 
increase in body weight and a gradual decrease of 
ALT activity from 4 to 17 weeks and 
albumin/globulin ratio from 0 to 17 weeks (Fig. 1B, 
C), confirming the advanced stages of chronic liver 
injury in both control and mutant livers (39). 
Fibrosis was then assessed by Sirius Red staining, 
which allows visualization of collagen fibers. 
Histologically, both control and mutant livers 
developed complete fibrosis patterns throughout the 
regions such as the P-C bridge (between the portal 
area and the central vein) and C-C bridge formations 
(between the central veins) (Fig. 1D), indicating 
micronodular cirrhosis (27). Unexpectedly, Fn-null 
livers developed more extended and significant 
fibrosis. Approximately 12% of the livers were 
Sirius Red positive, representing a 3.2-fold increase 
over control livers (Fig. 1D, P < 0.01). Taken 
together, these findings indicate that prolonged and 
persistent chronic damage caused by 17 weeks of 
CCl4 treatment does establish advanced liver 
fibrosis/micronodular cirrhosis in both control and 
Fn-null livers. 
 
Elevated myofibroblast activity in mutant livers.  
Myofibroblasts such as activated hepatic stellate 
cells play a central role in ECM remodeling upon 
liver injury. Immunofluorescence and Western 
analysis showed significantly more pronounced 
expression of α-smooth muscle actin (αSMA), a 
marker for myofibroblasts in Fn-null livers 
compared to controls at 17 weeks of CCl4 treatment 
(P < 0.05; Fig. 2A, B). There was no obvious 
apoptosis or cell death in either liver type as shown 
by cleaved caspase 3 immunostaining and no 
picnotic nuclei with Hoechst 33342 staining at 17 
weeks of CCl4 treatment (Fig. 2C and data not 
shown).  
 
Significant hepatic dysfunction and increased 
liver-tissue stiffness in mutant livers.   
Next, we examined whether a lack of Fn affects 
hepatic functions during chronic injury (Fig. 3A-C). 
Subsequent analyses of serum hepatic biochemical 
markers (total bilirubin as a measure of hepatic 
excretory function; cholinesterase and albumin as a 
measure of hepatic protein synthesis) revealed no 
apparent differences between control and mutant 
livers until 8 weeks of CCl4 treatment. In contrast, in 
the advanced stage at 17 weeks, mutant mice 
suffered from a significantly higher level of plasma 
total bilirubin (0.12 ± 0.02 mg/dl in control [n = 6] 
vs. 0.19 ± 0.04 mg/dl in mutant [n = 6], P = 0.0074) 
and lower level of cholinesterase (26.8 ± 1.5 IU/L in 
control [n = 6] vs. 23.4 ± 1.3 IU/L in mutant [n = 6], 
P = 0.025). Serum albumin levels were also 
decreased (3.37 ± 0.10 g/dl in control [n = 6] vs. 3.26 
± 0.15 g/dl in mutant [n = 6]) but without 
significance (P = 0.39). In addition, liver tissue 
stiffness as determined by AFM was significantly 
elevated in Fn-null livers compared to controls at 17 
weeks of CCl4 treatment (5,128 ± 553.6 MPa in 
mutant vs. 3,313 ± 835.2 MPa in control (n = 9); P < 
0.05, Fig. 3D-3G).   
 
Elevated production of latent TGF-β complexes 
and increased local TGF-β bioavailability in 
mutant livers.  
Fn is associated with latent TGF-β complexes when 
incorporated into the ECM (16,40) and local TGF-β 
activity is elevated in Fn-null livers in initial stages 
following liver injury (26,41). Hence, the effect of 
Fn-deficiency on the production of latent complexes 
of TGF-β and local TGF-β bioavailability during 
advanced chronic liver injury was also investiaged. 
Pronounced depositions of LAP and of LTBP-1, -3 
and -4 in the ECM of mutant livers were shown by 
immunohistochemistry at 17 weeks of CCl4 
treatment. Interestingly, fibrillar structures were 
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 7 
present even in the absence of Fn (Fig. 4A). 
Furthermore, the TGF-β activity in mutant livers was 
significantly higher than in controls at both 8 and 17 
weeks of CCl4 treatment (Fig. 4B, P < 0.05), 
indicating constitutively higher levels of active TGF-
β in Fn-null livers during chronic liver injury.   
    TGF-β promotes the initiation of myofibroblast 
phenotypes and TGF-β1 alone sufficiently initiates 
stellate cell activation and transdifferentiation into 
myofibroblasts after liver injury, whereas Fn extra 
domain-A (EDA) promotes stellate cell motility but 
not transdifferentiation into myofibroblasts in vitro 
(26,42). Latent TGF-β that is activated in response to 
injury binds to the TGF-β type I receptor, which then 
phosphorylates the C-terminal regions of Smad 2/3 
transcription factors. Activated Smads translocate to 
the nucleus where they are involved in the regulation 
of gene expression (43,44). Indeed, Fn-null livers 
showed a significantly increased number of nuclear 
phospho (p)-Smad2/3-positive nonparenchymal cells 
(P < 0.01) (Fig. 4C). Since constitutively elevated 
local TGF-β activity was demonstrated in Fn-null 
livers during chronic liver damage (P < 0.05, Fig. 
4B), the functional link between TGF-β and 
myofibroblastic phenotypes at 17 weeks of CCl4 
treatment was further addressed by double 
immunohistochemical staining. Fn-null livers 
showed a significantly increased number of p-
Smad2/3 and αSMA double-positive myofibroblasts 
(31.3 ± 5.5 cells/field in mutant; field = 0.37 mm2 [n 
= 10] vs. 9.8 ± 3.3 cells/field in control [n = 10], P < 
0.01) (Fig. 4D). No nuclear localization of p-
Smad2/3 was noted in either non-injured control or 
Fn-null livers (data now shown). 
 
More disorganized collagen networks with 
increased lysyl oxidase expressions in mutant 
livers.  
    Based on these data, we hypothesized that the 
collagenous ECM fibrillar network formed in the 
absence of Fn may differ functionally from Fn-
mediated collagenous fibrils, and the more extended 
fibrosis found in mutant livers (Fig. 1D) was 
associated with the impaired hepatic functions. 
Collagen network formation occurs as a multi-step 
process and contributes to ECM remodeling and 
maintenance upon tissue damage (45). Therefore, the 
expression, assembly and degradation levels of the 
major collagens, type I and III, in the advanced 
stages of chronic damage was next examined. 
Highly-disorganized collagen matrices were induced 
in Fn-null livers. Immunofluorescent observation 
revealed that extensive networks of type I and III 
collagen were diffusely distributed in the ECM (Fig. 
5A). Type I collagen mRNA levels was also 
significantly increased in Fn-null livers (P < 0.05, 
Fig. 5B). Collagen networks displayed more 
disorganized arrangements and significantly larger 
angular deviation in mutant livers as assessed by 
Sirius Red stained-samples under the polarized 
microscope (Fig. 5C-5E). In contrast, control livers 
formed well-organized, linear type III and type I 
collagen networks (Fig. 5A, 5C-5E). There were no 
significant differences in the expression of collagen-
related matrix metalloproteinase (MMP) MMP8 and 
MMP13 mRNA levels (Fig. 5F), suggesting that 
collagen degrading enzymes did not play major roles.    
    Since type V collagen is an essential element for 
type III/I collagen fibrillogenesis in vitro when Fn is 
absent (26), the contribution of type V collagen to 
advanced stages of chronic liver remodeling at 17 
weeks of CCl4 treatment was then determined. 
Significantly increased deposition and assembly of 
type V collagen was detected in Fn-null livers in 
comparison with controls and the localization of 
assembled fibrils often overlapped with type I 
collagen fibrils (Fig. 6A). Increased expression of 
type V collagen mRNA (~1.5-fold) was also 
observed in mutant livers compared to controls, 
although the difference was not statistically 
significant (Fig. 6B). Subsequent ultrastructural 
analysis using TEM revealed that the mean diameter 
of collagen fibrils was identical (47.0 ± 9.7 nm in 
mutant vs. 48.3 ± 8.9 nm in control [n = 1,500 fibrils 
in each]) (Fig. 6C, D). It is known that the diameter 
of formed type I collagen fibrils is inversely 
proportional to the type V/type I collagen ratio (46-
48). Indeed, a ~33% increase in the number of 
thinner (30-40 nm diameter) and a ~21% decrease in 
the number of thicker (50-60 nm diameter) collagen 
fibril-subpopulations was found in Fn-null livers 
compared to controls (Fig. 6D, right panel). Such 
thinner collagen fibril-subpopulations were also 
confirmed by AFM analysis (Fig. 3G). Importantly, 
a significantly increased number of collagen fibrils 
was demonstrated in mutant livers compared to 
controls (48.6 ± 7.0 fibrils/ 0.25 µm2 in mutant vs. 
41.7 ± 4.6 fibrils/ 0.25 µm2 in control (n = 18); P < 
0.01, Fig. 6E). The increased fibril number 
correlated with an increase in hepatic net collagen 
amount measured by hydroxyproline content (P < 
0.05, Fig. 6F). Thus, these results indicate that 
elimination of Fn results in thinner and increased 
number of collagen fibril organizations/assemblies 
and suggest both quantitative and qualitative 
differences between Fn- and type V collagen-
mediated type I collagen fibril network formation 
following tissue injury. 
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    Collagen crosslinking by LOX family members 
accompanies tissue fibrosis and stiffens tissues (12). 
Elevated expression of LOX and its subfamily, 
LOX-like protein (LOXL)2 is detected in both 
human fibrotic diseases and rodent injury models, 
and myofibroblasts such as activated hepatic stellate 
cells are the likely major cellular source of LOX in 
liver injury (49,50). Since significantly increased 
liver tissue stiffness alongside the deterioration of 
net hepatic function was demonstrated in Fn-null 
livers at 17 weeks of CCl4 treatment, the functional 
link between the lack of Fn and LOX expression 
levels was addressed. LOX and LOXL1-4 mRNA 
levels were all upregulated in Fn-null livers 
compared to controls, and LOX was found to be 
most upregulated in mutant livers (~2.64-fold) 
compared to controls (P < 0.01, Fig. 7A). Therefore, 
we determined whether elevated TGF-β 
bioavailability due to absence of Fn is directly 
involved in the production of LOX in activated 
hepatic stellate cells in vitro. The treatment of Fn-
null hepatic stellate cell lines with 2 pM TGF-β1 led 
to the release of a significant amount of active LOX 
proteins compared to parental cells (2.46 ± 0.13-fold 
upregulation in Fn-null vs. 1.60 ± 0.15-fold 
upregulation in control in response to TGF-β1, P < 
0.01), whereas no obvious differences in LOX 
protein levels were observed between them under 
untreated conditions (Fig. 7B). We further 
investigated the signaling axis for TGF-β1-mediated 
LOX expression in Fn-null hepatic stellate cells. 
Immunocytochemical analysis revealed a significant 
elevation of LOX expression in Fn-null hepatic 
stellate cells in response to TGF-β1 (Fig. 7C). 
Application of Smad3 inhibitor SIS3 following 
TGF-β1 treatment significantly inhibited (~42.0%) 
LOX expression in Fn-null hepatic stellate cells. In 
addition, PI3-kinase inhibitor LY294002 
significantly inhibited LOX expression (~38.1%), 
although to a lesser degree (Fig. 7C). This 
demonstrates the involvement of both canonical and 
non-canonical Smad such as PI3 kinase-mediated 
pathways in TGF-β1-mediated LOX expression in 
hepatic stellate cells. 
    Fn-null hepatic stellate cells do not organize type I 
collagen fibril network in culture, and TGF-β1 can 
induce type I collagen assembly (26). Therefore, the 
functional link between TGF-β1-induced LOX and 
structural and mechanical integrity of collagen fibril 
network in Fn-null hepatic stellate cells was 
addressed. Indeed, TGF-β1-induced collagen fibril 
stiffness in Fn-null hepatic stellate cells was 
significantly higher compared to control (parental) 
cells (Fig. 8A, P < 0.01). Treatment of Fn-null 
stellate cells with 2 pM TGF-β1 and LOX inhibitor 
β-aminopropionitrile (BAPN, 200 µM) resulted in 
the disruption of TGF-β-induced fine collagen fibril 
networks and significantly reduced collagen fibril 
stiffness (P < 0.01) (Fig. 8A, B). Importantly, 
treatment of Fn-null stellate cells with 10 µg/ml 
plasma Fn recovered collagen fibril stiffness to 
control (parental) cell levels (Fig. 8C). Thus, taken 
together, these findings indicate that elevated TGF-β 
bioavailability in Fn-null livers induces more active 
myofibroblasts and sustains their activated 
phenotypes. As a consequence of this, these 
myofibroblasts develop more accumulated, 
disorganized, and LOX-mediated tightly cross-
linked collagenous ECMs during advanced chronic 
liver damage, which thereby results in the significant 
deterioration of net hepatic function. 
 
 
 
Discussion 
 
Our current comprehensive genetic studies with a 
Fn-deficient animal model provide the following 
compelling evidence. (1) Elimination of Fn results in 
elevated local TGF-β activity and continuously 
increased intracellular TGF-β signaling in activated 
hepatic stellate cells (myofibroblasts). This results in 
the development of more advanced liver 
fibrosis/cirrhosis in Fn-null livers. (2) Fn-null livers 
exhibit significantly increased LOX expression in 
chronic liver injury, and Fn-null hepatic stellate cells 
are a target for the release of active LOX in response 
to TGF-β1 through both canonical and non-
canonical Smad pathways. Thus, we propose that 
there are the functional links between Fn-mediated 
control of TGF-β bioavailability and collagen fibril 
stiffness regulated by LOX. We suggest that such 
regulatory mechanisms by Fn could be translated for 
a potential therapeutic target in other chronic fibrotic 
diseases. 
    Our current findings in Fn-null mouse livers are 
consistent with the fact that elevated TGF-β activity 
induces enhanced differentiation and activation of 
quiescent fibroblastic cells with a myofibroblastic 
phenotype (induction of αSMA) in response to tissue 
damage (5,7). The expression level of αSMA is 
directly related to the contractile activity of 
myofibroblasts, which cause tissue contractures (51). 
This suggests that persistently elevated TGF-β 
activity due to the lack of Fn induces more highly 
contractile myofibroblasts and leads to greater ECM 
secretion accompanied with increased LOX-
mediated collagen crosslinking. However, collagen 
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network reorganization in adult tissues in response 
to injury is mediated by both Fn and TGF-β-induced 
type V collagen (26), and our results show both 
quantitative and qualitative differences between Fn- 
and type V collagen-mediated type I collagen fibril 
network formation. Therefore, while the contribution 
of type V collagen-nucleated collagen fibrogenesis 
in adult tissues is largely undetermined, our findings 
support the hypothesis that the accumulation of type 
V collagen-mediated ECMs during persistent 
chronic damage has an influence on disorganized 
ECM 3-dimensional architecture. Such phenotypes 
occurring beyond the early stages following tissue 
damage could contribute to the critical turning point 
from normal to abnormal healing in vivo. 
Consequently, more disorganized and rigid ECMs 
remarkably impede organ architecture and function. 
Indeed, accumulating evidence indicates that locally 
activated TGF-β plays a significant role in the 
development of liver fibrosis (52-54).   
    Earlier studies have shown that collagen cross-
linking mediated by LOX leads to cancer 
progression by enhancing ECM receptor integrin 
signaling (11) and that inhibition of LOX activity 
partially prevents tissue stiffness following injury 
(55). Consistent with previous in vitro and in vivo 
observations, (11,56,57), our findings indicate that 
inhibition of collagen cross linking by BAPN affects 
TGF-β-induced structural and mechanical integrity 
of collagenous ECM networks in Fn-null hepatic 
stellate cells. We have demonstrated functional links 
between tissue/organ functions and regulatory 
mechanisms of LOX underlying chronic fibrotic 
disease such as liver fibrosis/cirrhosis. Bone 
morphogenic protein 1 (BMP 1), an extracellular 
metalloproteinase, and periostin, a secretory protein 
in connective tissues, are major activators of LOX 
and interact with Fn (58,59). Fn-null embryonic 
fibroblasts dramatically decrease proteolytic 
processing of the 45 kDa LOX proenzyme to the 32 
kDa active form without changing BMP1 levels 
compared to control cells, suggesting the regulatory 
role of Fn matrix in LOX catalytic activity (60). In 
contrast, we have shown that Fn-null hepatic stellate 
cells release significant amount of active LOX in 
response to TGF-β1 without Fn matrix. Interestingly, 
this TGF-β1-LOX signaling axis in Fn-null hepatic 
stellate cells is mediated through both canonical and 
non-canonical pathways (61). A very recent 
observation has documented that the expression 
level of periostin is significantly upregulated in both 
acute and chronic liver injury, and TGF-β1 can 
induce periostin in hepatic stellate cells in vitro (62). 
Thus, periostin is likely to be involved in TGF-β1-
induced LOX activation in Fn-null hepatic stellate 
cells as cell type specific phenotyptes.  
    Little insight into the pathophysiological roles of 
Fn has emerged from studies of genetic changes in 
humans. There are no documented cases of Fn-null 
patients, the nearest condition being familial 
glomerulonephritis in which there are mutations in 
the type III modules of Fn (63). Whilst complete Fn-
null mice show an embryonic lethal phenotype (64), 
experimental evidence has documented that skin 
wounds heal normally in mice lacking plasma type 
Fn (30), hence an absolute requirement for Fn in 
response to adult tissue damage has been 
speculative. The current findings imply that Fn 
regulates the balance between active and inactive 
(latent) TGF-β, which in turn modulates ECM 
production and remodeling following injury, and 
consequently retains adult tissue/organ functions. A 
number of genetic studies suggest that the absence 
of, or a mutation in, LLC-binding ECMs such as 
fibrillin-1 and -2 results in increased TGF-β activity 
and Smad signaling, whereas the absence of, or 
mutation in, LTBPs results in decreased activity and 
signaling (65-70). We have demonstrated that the 
absence of Fn results in increased TGF-β 
bioavailability following organ injury. A possible 
explanation for elevated TGF-β bioavailability is 
that the deficiency of LLC-binding ECMs, as seen in 
this Fn-null model, decreases the matrix 
sequestration of LLCs, which thereby renders latent 
TGF-β more accessible for activation with negative 
consequences for cellular functions (71). In contrast, 
there were very limited in vivo observations for 
negative regulation of TGF-β bioavailability by Fn. 
A recent study reveals that the inhibition of cell-
mediated Fn matrix assembly without affecting its 
production by peptide pUR4 shows the normal 
release of active TGF-β in hepatic stellate cells in 
vitro (72). However, Fn matrix networks play crucial 
roles in many important biological events and in 
adult homeostasis (21,22). Fn matrix networks 
promote parenchymal cell survival such as 
hepatocytes following liver damage (23), and the 
elimination of Fn extradomain-A (EDA) splicing 
domain results in a shorter life span (73). Therefore, 
the regulation of TGF-β bioavailability by Fn with 
retaining Fn matrix networks would be essential 
elements for long-term anti-fibrotic strategies in 
chronic fibrotic diseases to preserve tissue/organ 
function and homeostasis.  
 
 
 by guest on N
ovem
ber 11, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 10
 
Acknowledgments 
We thank Zhuo Chang (School of Engineering, University of Liverpool) for expert technical assistance with the 
atomic force microscopy studies, and Dr. Masahide Yoshikawa for assistance of serological analysis. We also 
thank Dr. Harihara Baskaran for valuable comments and suggestions, and Dr. Emma Stephenson for editorial 
assistance. 
 
 
 
Grant Support 
This work was supported by National Institutes of Health research grant DK074538 (to T. Sakai). We are also 
grateful to the Institute of Translational Medicine, University of Liverpool for support (to T. Sakai.).  
 
 
 
Conflict of interest 
The authors disclose no conflicts.  
 
 
 
Author contributions 
Takao Sakai conceived ideas, designed experiments, and supervised the project. Ayumi Iwasaki, Keiko Sakai, Kei 
Moriya, Takayoshi Miyazono, and Satoshi Yasumura performed experiments. Douglas Keene carried out 
transmission electron microscopy studies, and Riaz Akhtar carried out atomic force microscopy studies. Takako 
Sasaki generated anti-type I, III and V collagen, LAP, LTBP-3 and 4, and LOX antibodies. Ayumi Iwasaki, Keiko 
Sakai, Kei Moriya, Riaz Akhtar, Takayoshi Miyazono, Satoshi Yasumura, Masatoshi Watanabe, Shin Morishita, 
and Takao Sakai analyzed the data. Takao Sakai wrote and edited the manuscript.  
 
 
 
  
 by guest on N
ovem
ber 11, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 11
References 
 
1. Diehl, A. M., and Chute, J. (2013) Underlying potential: cellular and molecular determinants of adult 
liver repair. The Journal of clinical investigation 123, 1858-1860 
2. Bataller, R., and Brenner, D. A. (2005) Liver fibrosis. The Journal of clinical investigation 115, 209-218 
3. Friedman, S. L. (2010) Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 7, 425-
436 
4. Schuppan, D., and Kim, Y. O. (2013) Evolving therapies for liver fibrosis. The Journal of clinical 
investigation 123, 1887-1901 
5. Wallace, K., Burt, A. D., and Wright, M. C. (2008) Liver fibrosis. Biochem J 411, 1-18 
6. Forbes, S. J., and Parola, M. (2011) Liver fibrogenic cells. Best practice & research. Clinical 
gastroenterology 25, 207-217 
7. Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M. L., and Gabbiani, G. (2007) The 
myofibroblast: one function, multiple origins. The American journal of pathology 170, 1807-1816 
8. Kolacna, L., Bakesova, J., Varga, F., Kostakova, E., Planka, L., Necas, A., Lukas, D., Amler, E., and 
Pelouch, V. (2007) Biochemical and biophysical aspects of collagen nanostructure in the extracellular 
matrix. Physiological research / Academia Scientiarum Bohemoslovaca 56 Suppl 1, S51-60 
9. Lucero, H. A., and Kagan, H. M. (2006) Lysyl oxidase: an oxidative enzyme and effector of cell function. 
Cell Mol Life Sci 63, 2304-2316 
10. Csiszar, K. (2001) Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res 
Mol Biol 70, 1-32 
11. Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F., Csiszar, K., Giaccia, 
A., Weninger, W., Yamauchi, M., Gasser, D. L., and Weaver, V. M. (2009) Matrix crosslinking forces 
tumor progression by enhancing integrin signaling. Cell 139, 891-906 
12. van der Slot, A. J., van Dura, E. A., de Wit, E. C., De Groot, J., Huizinga, T. W., Bank, R. A., and 
Zuurmond, A. M. (2005) Elevated formation of pyridinoline cross-links by profibrotic cytokines is 
associated with enhanced lysyl hydroxylase 2b levels. Biochim Biophys Acta 1741, 95-102 
13. Gressner, A. M., Weiskirchen, R., Breitkopf, K., and Dooley, S. (2002) Roles of TGF-beta in hepatic 
fibrosis. Front Biosci 7, d793-807 
14. Hayashi, H., and Sakai, T. (2012) Biological Significance of Local TGF-beta Activation in Liver 
Diseases. Frontiers in physiology 3, 12 
15. Dallas, S. L., Sivakumar, P., Jones, C. J., Chen, Q., Peters, D. M., Mosher, D. F., Humphries, M. J., and 
Kielty, C. M. (2005) Fibronectin regulates latent transforming growth factor-beta (TGF beta) by 
controlling matrix assembly of latent TGF beta-binding protein-1. The Journal of biological chemistry 
280, 18871-18880 
16. Rifkin, D. B. (2005) Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of 
TGF-beta availability. The Journal of biological chemistry 280, 7409-7412 
17. Margadant, C., and Sonnenberg, A. (2010) Integrin-TGF-beta crosstalk in fibrosis, cancer and wound 
healing. EMBO Rep 11, 97-105 
18. Sheppard, D. (2006) Transforming growth factor beta: a central modulator of pulmonary and airway 
inflammation and fibrosis. Proc Am Thorac Soc 3, 413-417 
19. Varga, J., and Pasche, B. (2009) Transforming growth factor beta as a therapeutic target in systemic 
sclerosis. Nat Rev Rheumatol 5, 200-206 
20. Nishimura, S. L. (2009) Integrin-mediated transforming growth factor-beta activation, a potential 
therapeutic target in fibrogenic disorders. The American journal of pathology 175, 1362-1370 
21. Hynes, R. O. (1990) Fibronectins, Springer-Verlag, New York 
22. Mosher, D. F. (1989) Fibronectin, Academic Press, San Diego 
23. Moriya, K., Sakai, K., Yan, M. H., and Sakai, T. (2012) Fibronectin is essential for survival but is 
dispensable for proliferation of hepatocytes in acute liver injury in mice. Hepatology (Baltimore, Md.) 56, 
311-321 
24. Velling, T., Risteli, J., Wennerberg, K., Mosher, D. F., and Johansson, S. (2002) Polymerization of type I 
and III collagens is dependent on fibronectin and enhanced by integrins alpha 11beta 1 and alpha 2beta 1. 
The Journal of biological chemistry 277, 37377-37381 
 by guest on N
ovem
ber 11, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 12
25. Sottile, J., Shi, F., Rublyevska, I., Chiang, H. Y., Lust, J., and Chandler, J. (2007) Fibronectin-dependent 
collagen I deposition modulates the cell response to fibronectin. Am J Physiol Cell Physiol 293, C1934-
1946 
26. Moriya, K., Bae, E., Honda, K., Sakai, K., Sakaguchi, T., Tsujimoto, I., Kamisoyama, H., Keene, D. R., 
Sasaki, T., and Sakai, T. (2011) A fibronectin-independent mechanism of collagen fibrillogenesis in adult 
liver remodeling. Gastroenterology 140, 1653-1663 
27. Constandinou, C., Henderson, N., and Iredale, J. P. (2005) Modeling liver fibrosis in rodents. Methods 
Mol Med 117, 237-250 
28. Nowack, H., Gay, S., Wick, G., Becker, U., and Timpl, R. (1976) Preparation and use in 
immunohistology of antibodies specific for type I and type III collagen and procollagen. J Immunol 
Methods 12, 117-124 
29. Timpl, R. (1982) Antibodies to collagens and procollagens. Methods in enzymology 82 Pt A, 472-498 
30. Sakai, T., Johnson, K. J., Murozono, M., Sakai, K., Magnuson, M. A., Wieloch, T., Cronberg, T., Isshiki, 
A., Erickson, H. P., and Fassler, R. (2001) Plasma fibronectin supports neuronal survival and reduces 
brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and 
hemostasis. Nat Med 7, 324-330 
31. Sakai, T., Li, S., Docheva, D., Grashoff, C., Sakai, K., Kostka, G., Braun, A., Pfeifer, A., Yurchenco, P. 
D., and Fassler, R. (2003) Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell 
adhesion, and controlling actin accumulation. Genes Dev 17, 926-940 
32. Maeda, T., Sakabe, T., Sunaga, A., Sakai, K., Rivera, A. L., Keene, D. R., Sasaki, T., Stavnezer, E., 
Iannotti, J., Schweitzer, R., Ilic, D., Baskaran, H., and Sakai, T. (2011) Conversion of mechanical force 
into TGF-beta-mediated biochemical signals. Curr Biol 21, 933-941 
33. Whittaker, P., and Przyklenk, K. (2009) Fibrin architecture in clots: a quantitative polarized light 
microscopy analysis. Blood Cells Mol Dis 42, 51-56 
34. Katoh, K., Hammar, K., Smith, P. J., and Oldenbourg, R. (1999) Arrangement of radial actin bundles in 
the growth cone of Aplysia bag cell neurons shows the immediate past history of filopodial behavior. 
Proc Natl Acad Sci U S A 96, 7928-7931 
35. Madibally, S. V., Solomon, V., Mitchell, R. N., Van De Water, L., Yarmush, M. L., and Toner, M. (2003) 
Influence of insulin therapy on burn wound healing in rats. J Surg Res 109, 92-100 
36. Papi, M., Paoletti, P., Geraghty, B., and Akhtar, R. (2014) Nanoscale characterization of the 
biomechanical properties of collagen fibrils in the sclera. Applied Physics Letters 104, 103703 
37. Honda, K., Sakaguchi, T., Sakai, K., Schmedt, C., Ramirez, A., Jorcano, J. L., Tarakhovsky, A., 
Kamisoyama, H., and Sakai, T. (2007) Epidermal hyperplasia and papillomatosis in mice with a 
keratinocyte-restricted deletion of csk. Carcinogenesis 28, 2074-2081 
38. Abe, M., Harpel, J. G., Metz, C. N., Nunes, I., Loskutoff, D. J., and Rifkin, D. B. (1994) An assay for 
transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 
promoter-luciferase construct. Anal Biochem 216, 276-284 
39. Schuppan, D., and Afdhal, N. H. (2008) Liver cirrhosis. Lancet 371, 838-851 
40. Hynes, R. O. (2009) The extracellular matrix: not just pretty fibrils. Science 326, 1216-1219 
41. Kawelke, N., Vasel, M., Sens, C., Au, A., Dooley, S., and Nakchbandi, I. A. (2011) Fibronectin protects 
from excessive liver fibrosis by modulating the availability of and responsiveness of stellate cells to 
active TGF-beta. PLoS One 6, e28181 
42. Olsen, A. L., Sackey, B. K., Marcinkiewicz, C., Boettiger, D., and Wells, R. G. (2012) Fibronectin extra 
domain-A promotes hepatic stellate cell motility but not differentiation into myofibroblasts. 
Gastroenterology 142, 928-937 e923 
43. Massague, J., Seoane, J., and Wotton, D. (2005) Smad transcription factors. Genes Dev 19, 2783-2810 
44. Moustakas, A., and Heldin, C. H. (2009) The regulation of TGFbeta signal transduction. Development 
136, 3699-3714 
45. Canty, E. G., and Kadler, K. E. (2005) Procollagen trafficking, processing and fibrillogenesis. Journal of 
cell science 118, 1341-1353 
46. Adachi, E., and Hayashi, T. (1986) In vitro formation of hybrid fibrils of type V collagen and type I 
collagen. Limited growth of type I collagen into thick fibrils by type V collagen. Connect Tissue Res 14, 
257-266 
 by guest on N
ovem
ber 11, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 13
47. Wenstrup, R. J., Florer, J. B., Brunskill, E. W., Bell, S. M., Chervoneva, I., and Birk, D. E. (2004) Type V 
collagen controls the initiation of collagen fibril assembly. The Journal of biological chemistry 279, 
53331-53337 
48. Birk, D. E. (2001) Type V collagen: heterotypic type I/V collagen interactions in the regulation of fibril 
assembly. Micron 32, 223-237 
49. Perepelyuk, M., Terajima, M., Wang, A. Y., Georges, P. C., Janmey, P. A., Yamauchi, M., and Wells, R. 
G. (2013) Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl 
oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol 304, G605-614 
50. Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., 
Vaysberg, M., Ghermazien, H., Wai, C., Garcia, C. A., Velayo, A. C., Jorgensen, B., Biermann, D., Tsai, 
D., Green, J., Zaffryar-Eilot, S., Holzer, A., Ogg, S., Thai, D., Neufeld, G., Van Vlasselaer, P., and Smith, 
V. (2010) Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic 
microenvironment. Nat Med 16, 1009-1017 
51. Guyot, C., Lepreux, S., Combe, C., Doudnikoff, E., Bioulac-Sage, P., Balabaud, C., and Desmouliere, A. 
(2006) Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem 
Cell Biol 38, 135-151 
52. Kondou, H., Mushiake, S., Etani, Y., Miyoshi, Y., Michigami, T., and Ozono, K. (2003) A blocking 
peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. Journal of 
hepatology 39, 742-748 
53. Drews, F., Knobel, S., Moser, M., Muhlack, K. G., Mohren, S., Stoll, C., Bosio, A., Gressner, A. M., and 
Weiskirchen, R. (2008) Disruption of the latent transforming growth factor-beta binding protein-1 gene 
causes alteration in facial structure and influences TGF-beta bioavailability. Biochim Biophys Acta 1783, 
34-48 
54. Wang, B., Dolinski, B. M., Kikuchi, N., Leone, D. R., Peters, M. G., Weinreb, P. H., Violette, S. M., and 
Bissell, D. M. (2007) Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology (Baltimore, Md.) 
46, 1404-1412 
55. Georges, P. C., Hui, J. J., Gombos, Z., McCormick, M. E., Wang, A. Y., Uemura, M., Mick, R., Janmey, 
P. A., Furth, E. E., and Wells, R. G. (2007) Increased stiffness of the rat liver precedes matrix deposition: 
implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 293, G1147-1154 
56. Zhao, R., Chen, C. S., and Reich, D. H. (2014) Force-driven evolution of mesoscale structure in 
engineered 3D microtissues and the modulation of tissue stiffening. Biomaterials 35, 5056-5064 
57. Mammoto, A., Mammoto, T., Kanapathipillai, M., Wing Yung, C., Jiang, E., Jiang, A., Lofgren, K., Gee, 
E. P., and Ingber, D. E. (2013) Control of lung vascular permeability and endotoxin-induced pulmonary 
oedema by changes in extracellular matrix mechanics. Nature communications 4, 1759 
58. Huang, G., Zhang, Y., Kim, B., Ge, G., Annis, D. S., Mosher, D. F., and Greenspan, D. S. (2009) 
Fibronectin binds and enhances the activity of bone morphogenetic protein 1. The Journal of biological 
chemistry 284, 25879-25888 
59. Maruhashi, T., Kii, I., Saito, M., and Kudo, A. (2010) Interaction between periostin and BMP-1 promotes 
proteolytic activation of lysyl oxidase. The Journal of biological chemistry 285, 13294-13303 
60. Fogelgren, B., Polgar, N., Szauter, K. M., Ujfaludi, Z., Laczko, R., Fong, K. S., and Csiszar, K. (2005) 
Cellular fibronectin binds to lysyl oxidase with high affinity and is critical for its proteolytic activation. 
The Journal of biological chemistry 280, 24690-24697 
61. Voloshenyuk, T. G., Landesman, E. S., Khoutorova, E., Hart, A. D., and Gardner, J. D. (2011) Induction 
of cardiac fibroblast lysyl oxidase by TGF-beta1 requires PI3K/Akt, Smad3, and MAPK signaling. 
Cytokine 55, 90-97 
62. Huang, Y., Liu, W., Xiao, H., Maitikabili, A., Lin, Q., Wu, T., Huang, Z., Liu, F., Luo, Q., and Ouyang, 
G. (2015) Matricellular protein periostin contributes to hepatic inflammation and fibrosis. The American 
journal of pathology 185, 786-797 
63. Castelletti, F., Donadelli, R., Banterla, F., Hildebrandt, F., Zipfel, P. F., Bresin, E., Otto, E., Skerka, C., 
Renieri, A., Todeschini, M., Caprioli, J., Caruso, R. M., Artuso, R., Remuzzi, G., and Noris, M. (2008) 
Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A 105, 2538-
2543 
 by guest on N
ovem
ber 11, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 14
64. George, E. L., Georges-Labouesse, E. N., Patel-King, R. S., Rayburn, H., and Hynes, R. O. (1993) 
Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. 
Development 119, 1079-1091 
65. Neptune, E. R., Frischmeyer, P. A., Arking, D. E., Myers, L., Bunton, T. E., Gayraud, B., Ramirez, F., 
Sakai, L. Y., and Dietz, H. C. (2003) Dysregulation of TGF-beta activation contributes to pathogenesis in 
Marfan syndrome. Nature genetics 33, 407-411 
66. Nistala, H., Lee-Arteaga, S., Smaldone, S., Siciliano, G., Carta, L., Ono, R. N., Sengle, G., Arteaga-Solis, 
E., Levasseur, R., Ducy, P., Sakai, L. Y., Karsenty, G., and Ramirez, F. (2010) Fibrillin-1 and -2 
differentially modulate endogenous TGF-beta and BMP bioavailability during bone formation. The 
Journal of cell biology 190, 1107-1121 
67. Koli, K., Wempe, F., Sterner-Kock, A., Kantola, A., Komor, M., Hofmann, W. K., von Melchner, H., and 
Keski-Oja, J. (2004) Disruption of LTBP-4 function reduces TGF-beta activation and enhances BMP-4 
signaling in the lung. The Journal of cell biology 167, 123-133 
68. Yoshinaga, K., Obata, H., Jurukovski, V., Mazzieri, R., Chen, Y., Zilberberg, L., Huso, D., Melamed, J., 
Prijatelj, P., Todorovic, V., Dabovic, B., and Rifkin, D. B. (2008) Perturbation of transforming growth 
factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors. 
Proc Natl Acad Sci U S A 105, 18758-18763 
69. Loeys, B. L., Gerber, E. E., Riegert-Johnson, D., Iqbal, S., Whiteman, P., McConnell, V., Chillakuri, C. 
R., Macaya, D., Coucke, P. J., De Paepe, A., Judge, D. P., Wigley, F., Davis, E. C., Mardon, H. J., 
Handford, P., Keene, D. R., Sakai, L. Y., and Dietz, H. C. (2010) Mutations in fibrillin-1 cause congenital 
scleroderma: stiff skin syndrome. Sci Transl Med 2, 23ra20 
70. Mazzieri, R., Jurukovski, V., Obata, H., Sung, J., Platt, A., Annes, E., Karaman-Jurukovska, N., Gleizes, 
P. E., and Rifkin, D. B. (2005) Expression of truncated latent TGF-beta-binding protein modulates TGF-
beta signaling. Journal of cell science 118, 2177-2187 
71. Ramirez, F., and Rifkin, D. B. (2009) Extracellular microfibrils: contextual platforms for TGFbeta and 
BMP signaling. Curr Opin Cell Biol 21, 616-622 
72. Altrock, E., Sens, C., Wuerfel, C., Vasel, M., Kawelke, N., Dooley, S., Sottile, J., and Nakchbandi, I. A. 
(2015) Inhibition of fibronectin deposition improves experimental liver fibrosis. Journal of hepatology 
62, 625-633 
73. Muro, A. F., Chauhan, A. K., Gajovic, S., Iaconcig, A., Porro, F., Stanta, G., and Baralle, F. E. (2003) 
Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal 
lifespan. The Journal of cell biology 162, 149-160 
 
 
 
Abbreviations  
αSMA, α-smooth muscle actin; ALT, alanine aminotransferase; AFM, atomic force microscopy; BAPN, β-
aminopropionitrile; BMP 1, Bone morphogenic protein 1; CCl4, carbon tetrachloride; DAPI, 4’6-diamidino-2-
phenylindole; ECM, extracellular matrix; FITC, fluorescein isothiocyanate; Fn, fibronectin; LAP, latency 
associated protein; LLC, large latent complex; LOX, lysyl oxidase; LTBP, latent TGF-β-binding protein; MMP, 
matrix metalloproteinase; mAb, monoclonal antibody; PCR, polymerase chain reaction; pAb, polyclonal 
antibody; pI-pC, polyinosinic-polycytidic acid; PVDF, polyvinylidene fluoride; TEM, transmission electron 
microscopy; TGF-β, transforming growth factor-β 
 by guest on N
ovem
ber 11, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 15
Figure Legends 
 
Fig. 1. Liver fibrosis/cirrhosis developing during CCl4-induced (0.5 ml/kg weight) chronic liver injury is greater 
in mice lacking liver Fn (Control, wild-type with CCl4; LivFn-null, mutant with CCl4; Untreated, wild-type 
without CCl4 treatment).  
(A) Generation of advanced chronic liver fibrosis/cirrhosis by CCl4 in mice lacking liver Fn (Fn(f/f)/Mx-Cre+). 
(Upper panels) Western blot analysis of Fn (plasma and cellular types) in liver tissue lysates from control and 
mutant mice before (0 week) and at 17 weeks of CCl4 treatment. (Lower panel) Analysis of Fn intensities at 17 
weeks of CCl4 treatment. Fn expression levels are shown relative to the control value of 100 (percent of control). 
Error bars represent standard deviation (n = 5 for each group). Note that the depletion of Fn in mutant livers is 
~98% (**, P < 0.01). 
(B) Analysis of body weight. Data are means ± S.D. (n = 5 for each group). Note that both control and mutant 
body weights show similar patterns during the continuous phase of hepatic damage caused by CCl4. 
(C) Serum alanine aminotransferase (ALT) levels and albumin/globulin (A/G) ratio. Data are means ± S.D. (n = 6 
for each group). Note that while both ALT levels and A/G ratio are gradually decreased in both control and 
mutant mice, they show similar patterns throughout the process.  
(D) Upper panels: Mice lacking Fn develop more pronounced liver fibrosis/cirrhosis, as identified by Sirius Red 
staining at 17 weeks of CCl4 treatment. Bar = 100 µm. Lower panel: Quantification of fibrosis at 17 weeks of 
CCl4 treatment based on Sirius Red staining. Data are means ± S.D. (n = 5 for each group). Note that significantly 
more fibrosis is induced in mutant livers compared to controls (**, P < 0.01).  
 
Fig. 2. Significantly elevated myofibroblast activity in Fn-null livers at 17 weeks of CCl4 treatment. 
(A) Left panels: Expression of αSMA (in red) shown by immunofluorescence staining at 0 (untreated) and 17 
weeks of CCl4 treatment. Bar = 100 µm. Right panel: Quantification of αSMA positive areas at 17 weeks of CCl4 
treatment (large blood vessel-positive areas [b] shown in left panels were subtracted). Data are means ± S.D. (n = 
4 in each group; **, P < 0.01).  
(B) Left panel: Western blot analysis of myofibroblast marker αSMA protein expression at 17 weeks of CCl4 
treatment. Right panel: Analysis of αSMA intensities. Band intensity was measured by densitometry and 
normalized to β-actin (loading control). The αSMA expression levels are shown relative to the control value of 
100 (percent of control). Data are means ± S.D. (n = 3 for control and 4 for null mice; *, P < 0.05).  
 (C) Immunostaining for cleaved caspase 3 (caspase 3 in brown; nuclei in blue). Note that no apparent positive 
cells are visible. Bar = 25 µm.   
 
Fig. 3. Significant hepatic dysfunction and increased liver-tissue stiffness in Fn-null livers. 
(A) - (C) Serum levels of the hepatic biochemical markers total bilirubin (A), cholinesterase (B), and albumin (C) 
during chronic liver injury. Data are means ± S.D. (n = 6 for each group). Note that considerable loss of hepatic 
functional reserve is demonstrated in mutant livers, as evidenced by significant upregulation of total bilirubin and 
downregulation of cholinesterase levels (*, P < 0.05; **, P < 0.01).  
(D) - (G) Analysis of liver tissue stiffness using AFM at 17 weeks of CCl4 treatment.  
(D) Elastic modulus in liver tissues. Data are means ± S.D. Note that elastic modulus are significantly higher in 
mutant livers (n [measured areas] = 9 for each group *, P  < 0.05). 
(E) Gaussian fit of elastic modulus distribution determined pixel-by-pixel with the Peakforce method in a typical 
collagen fibril-rich area in each group (2 x 2 µm images were used for this analysis). 
(F, G) AFM images showing (F) a map of mechanical properties (log of the elastic modulus) and (G) topography 
(height) of collagen fibrils in control and Fn-null liver at 17 weeks of CCl4 treatment. Note that mutant livers 
show thinner and more dispersed fibrils. 
  
Fig. 4. Lack of Fn results in elevated accumulation of latent TGF-β complexes and continuous activation of TGF-
β during chronic liver injury.  
(A) Significantly increased accumulation of LAP and LTBP-1, -3 and -4 (in red) in the ECM of mutant livers at 
17 weeks of CCl4 treatment shown by immunofluorescence staining using serial sections (**, P < 0.01). Bar = 
100 µm.  
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(B) Active TGF-β bioassay at 8 and 17 weeks of CCl4 treatment. Data are means ± S.D. (n = 6 for each group). 
Note that mutant livers show significantly elevated local TGF-β activity at both time points (*, P < 0.05; **, P < 
0.01). 
(C) Left panels: Immunostaining for pSmad2/3. Sections were counterstained with hematoxylin. Bar = 25 µm. 
Right panel: Analysis of pSmad2/3-positive cells. Data are means ± S.D. (n = 10 in each group). Note that the 
number of nuclear pSmad2/3-positive (in brown) non-parenchymal cells (NPCs; red arrowheads) in mutant livers 
is significantly higher than controls at 17 weeks of CCl4 treatment (**, P < 0.01). For comparison, hepatocyte 
nuclei (~two- to three-hold larger than those in non-parenchymal cells) are indicated (black arrows). 
(D) Left panels: Double immunohistochemical staining for pSmad2/3 (in purple/blue) and αSMA (in brown). 
Note that the nuclear pSmad2/3-positive cells express myofibroblast marker αSMA in their cytoplasms (black 
arrowheads). Bar = 25 µm. Right panel: Analysis of pSmad2/3 and αSMA double-positive myofibroblasts. Data 
are means ± S.D. (n = 10 in each group; **, P < 0.01). 
 
Fig. 5. Fn-null livers accumulate more extensive and disorganized collagen fibril networks at 17 weeks of CCl4 
treatment.  
(A) Upper panels: Deposition of type III and type I collagens at 0 (untreated) and 17 weeks of CCl4 treatment by 
immunofluorescent staining. Depositions at 17 weeks are shown using serial sections. Bar = 100 µm. Lower 
panels: Quantification of positive areas at 17 weeks of CCl4 treatment. Data are means ± S.D. (n = 4 for each 
group). Note that deposition of type III and type I collagen is significantly increased in mutant livers compared to 
controls at 17 weeks of CCl4 treatment (**, P < 0.01).  
(B) Real-time PCR analysis of Col1a1 mRNA levels. Relative mRNA expression levels are shown relative to the 
control value of 1. Data are means ± S.D. (n = 5 for each group). Note that collagen mRNA levels in mutant livers 
are significantly upregulated (*, P < 0.05).  
(C) - (E) Analysis of assembled fibrils using polarized microscopy.  
(C) Immunofluorescent staining for type I collagen (first upper 2 panels), and representative images of retardance 
and orientation by Sirius Red-stained serial sections (second and third 2 panels, respectively). The level of 
retardation is denoted by a pixel color, as indicated by the color legend (from purple [the lowest] to red [the 
highest]). Note that the maximum magnitude of retardance (red color) is identical in the control and mutant liver. 
Bars = 25 µm.  
(D) Representative distribution patterns of fibril bundle orientation in the control and mutant livers. The x-axis 
represents the orientation angle. This is divided into 10° increments and 0° corresponds to the mean orientation of 
distributions. The y-axis shows the percentage of fibril bundles within 10° orientation angle range. Note that 
orientation of fibril bundles in mutant livers is less aligned and more disorganized compared to controls. AD, 
angular deviation.   
(E) The average angular deviation of orientation distributions. Data are means ± S.D. Note that angular deviation 
is significantly larger in mutant livers (**, P < 0.01).  
(F) Real-time PCR analysis of MMP8 and MMP13 mRNA levels. Relative mRNA expression levels are shown 
relative to the control value of 1. Data are means ± S.D. (n = 5 for each group). Note that the expression levels are 
not significantly different.  
 
Fig. 6. Contribution of type V collagen to advanced chronic liver injury and collagen fibril ultrastructure at 17 
weeks of CCl4 treatment.  
(A) Significantly increased deposition and assembly of type V collagen in mutant livers shown by 
immunofluorescence staining using serial sections (type V collagen in green; type I collagen in red; Fn in red; 
DAPI [cell nuclei] in blue) (n = 4 for each group; **, P < 0.01). Bar = 50 µm. 
(B) Real-time PCR analysis of Col5a1 mRNA levels. Relative mRNA expression levels are shown relative to the 
control value of 1.0. Data are means ± S.D. (n = 4 for each group). Note that expression levels in mutant livers are 
~1.5-fold increased but not significantly different.  
(C) - (F) Ultrastructural analysis of collagen fibrils using TEM.  
(C) Electron micrographs of longitudinal (upper panel) and transverse (lower panel) sections. Bar = 100 nm.  
(D) Left panel: The average diameter of collagen fibrils (1,500 fibrils for each group: 375 fibrils per animal, n = 4, 
were calculated). Note that the average fibril diameter is identical between control and mutant livers. Right panel: 
Morphometric analysis of collagen fibril diameter (1,500 fibrils for each group: 375 fibrils per animal, n = 4, were 
 by guest on N
ovem
ber 11, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 17
calculated). Note the ~33% increase in the thinner (30-40 nm diameter) and the ~21% decrease in the number of 
thicker (50-60 nm diameter) collagen fibril-subpopulations evident in mutant livers.  
(E) Collagen fibril number. Data are means ± S.D. Note that the fibril number is significantly higher in mutant 
livers (n [measured areas] = 18 for each group **, P  < 0.01).  
(F) Hydroxyproline contents. Data are means ± S.D. (n = 4 for each group). Note that net hepatic collagen content 
in mutant livers is significantly increased (*, P < 0.05).  
 
Fig. 7. Elevated LOX expression level in Fn-null liver at 17 weeks of CCl4 treatment and its mechanism. 
(A) Real-time PCR analysis of LOX and LOXL1-4 mRNA levels in control and mutant livers. Relative mRNA 
expression levels are shown relative to the control value of 1. Error bars represent standard deviation (n = 4 for 
each group; *, P < 0.05; **, P < 0.01).  
(B) Left panels: Western blot analysis of LOX in Fn-null and its parental hepatic stellate cell (HSC) lines with or 
without treatment of 2 pM TGF-β1 in vitro. Aorta tissue lysates from adult wild-type mice were used as a positive 
control. Right panel: Analysis of induction levels of active LOX in response to TGF-β1 (fold increase). Band 
intensity was measured by densitometry and normalized to HSC70 (loading control). Data are from three 
independent experiments. **, P < 0.01. 
(C) Left Panels: Double immunofluorescence staining for LOX (in green) and DAPI (in blue) in Fn-null hepatic 
stellate cells (HSC) cultured for 18 h with or without 2 pM TGF-β1 treatment. Bar = 25 µm. Right panel: The 
effect of Smad3 inhibitor SIS3, PI3-kinase inhibitor LY294002, p38 MAP kinase inhibitor PD169316, JNK 
inhibitor 420119, and MEK1/2 inhibitor PD98059 on TGF-β1 induced LOX expression in Fn-null hepatic stellate 
cells.  Data are means ± S.D. **, P < 0.01. 
 
Fig. 8. Structural and mechanical integrity of formed collagen fibril networks in Fn-null hepatic stellate cells. 
(A) Elastic modulus of collagen fibrils in Fn-null hepatic stellate cells without treatment (Ntx) or with TGF-β1 or 
TGF-β1 plus 200 µM BAPN, and parental (control) cells without treatment cultured for 7 days. Data are means ± 
S.D. (n [measured areas] = 7 for Fn-null cells; 6 for parental cells. **, P  < 0.01). #, Fn-null stellate cells do not 
form collagen fibril network in culture without treatment (26).  
(B) Immunofluorescence staining for type I collagen (in red) (upper panels) and images showing a peak force 
error by AFM (lower panels) in Fn-null hepatic stellate cells (HSC) cultured for 7 days with TGF-β1 or TGF-β1 
plus 200 µM BAPN. Bar in fluorescence staining = 25 µm. Note that BAPN treatment results in the disruption of 
longitudinal collagen bundle formation.  
(C) Elastic modulus of collagen fibrils in Fn-null hepatic stellate cells with 10 µg/ml plasma Fn and parental 
(control) cells cultured for 7 days. Data are means ± S.D. (n [measured areas] = 6 for each group). n.s., not 
significantly different.  
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